Tel: 732-484-9848
Fax: 888-484-5008
Email: sales@chemscene.com
   
Buliding blocks
Intermediates
Bioactive molecules
Product Pathways
All Targets
Anti-infection
Antibody-drug conjugate....
Apoptosis
Biochemical Reagent
Cell Cycle/DNA Damage
GPCR/G protein
Immunology/Inflammation
JAK/STAT Signaling
MAPK/ERK Pathway
Membrane Transporter/Io....
Metabolism/Protease
Microbiology
Neuronal Signaling
NF-KB
Others
PI3K/Akt/mTOR
Protein Tyrosine Kinase....
TGF-beta/Smad
Vitamin D Related
Wnt/Hedgehog/Notch
Research Area
Cancer
Cardiovascular Disease
Endocrinology
Infection
Metabolic Disease
Neurological Disease
Others
Inflammation/Immunology
Product Type
All Products
New Products
Featured Products
Home   »   Product Pathways  »  Cancer  »  (+)-JQ-1

Products are for research use only. Not for human use. We do not sell to patients.


CS-0581 (+)-JQ-1


(JQ-1;JQ1)
Structure Price and Availability of    (+)-JQ-1
United States
Size Price Stock
5mg $99 In-stock Inquiry
1g Get quote
5g Get quote
>10g Get quote
 Distributor In Japan:  フナコシ株式会社 www.funakoshi.co.jp    
電話番号:81-3-5684-1620    FAX番号:81-3-5684-1775
Inquiry for price and availability only. Please place your order via our email or fax.
Contact us for competitive discounts on bulk quantities .
  • Data Sheet
  • Introduction
  • References
  • Related Products

(+)-JQ-1  M.Wt: 456.99
(+)-JQ-1  Formula: C23H25ClN4O2S
(+)-JQ-1  Solubility: DMSO >150 mg/mL; Water <1 mg/mL; Ethanol 125 mg/mL
(+)-JQ-1  Purity: >98%
(+)-JQ-1  Storage:  Please store the product under the recommended conditions in the Certificate of Analysis.
CAS: 1268524-70-4

View current batch:

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2). IC50 Value: 77 nM(for BRD4(1)); 33 nM( for BRD4(2)) Target: BRD4 in vitro: (+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. in vivo: (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts.

1 . Selective inhibition of BET bromodomains By Filippakopoulos, Panagis; Qi, Jun; Picaud, Sarah; Shen, Yao; Smith, William B.; Fedorov, Oleg; Morse, Elizabeth M.; Keates, Tracey; Hickman, Tyler T.; Felletar, Ildiko; et al From Nature. 2010 Dec 23;468(7327):1067-73. Epub 2010 Sep 24.
Abstract
Epigenetic proteins are intently pursued targets in ligand discovery. So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'. Potent inhibitors of histone binding modules have not yet been described. Here we report a cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains. High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity. Recurrent translocation of BRD4 is observed in a genetically-defined, incurable subtype of human squamous carcinoma. Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models. ...

BET bromodomain  |  
Keywords: buy (+)-JQ-1 | (+)-JQ-1 Supplier | purchase (+)-JQ-1 | (+)-JQ-1 cost | (+)-JQ-1 manufacturer | order (+)-JQ-1 | (+)-JQ-1 distributor | (+)-JQ-1 structure,chemscene
buy 1268524-70-4 | 1268524-70-4 Supplier | purchase 1268524-70-4 | 1268524-70-4 cost | 1268524-70-4 manufacturer | order 1268524-70-4 | 1268524-70-4 distributor | 1268524-70-4 structure,chemscene


CHEMSCENE, LLC
Tel: 732-484-9848
Fax: 888-484-5008
Email:  sales@chemscene.com
Address: 11 Deer Park Drive, Suite 102D Monmouth Junction, NJ 08852.
Products are for research use only. Not for human use. We do not sell to patients. Sitemap | Inhibitor © Copyright 2012. All Rights Reserved.